Metformin: Nonglycemic effects and potential novel indications

Endocrine Practice

Volumn 22, Issue 8, 2016, Pages 999-1007

  Anabtawi, Abeer ^a   Miles, John M ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; METFORMIN; NORADRENALIN; PHENFORMIN; WARFARIN; GLUCOSE BLOOD LEVEL;

BLOOD PRESSURE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; DRUG MECHANISM; DRUG SAFETY; ENERGY BALANCE; ESTIMATED GLOMERULAR FILTRATION RATE; HEART FAILURE; HEART INDEX; HUMAN; KIDNEY FUNCTION; LACTIC ACIDOSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION; ANIMAL; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DRUG REPOSITIONING; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; METABOLISM; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; TRENDS;

ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG REPOSITIONING; ENERGY METABOLISM; HUMANS; METFORMIN; RENAL INSUFFICIENCY, CHRONIC;

EID: 84993670443     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP151145.RA     Document Type: Review

References (99)

1. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-1972.
2. Garber A, Abrahamson M, Barzilay J, et al. AACE/ACE comprehensive type 2 diabetes management algorithm 2016. Endocr Pract. 2016;22:84-113.
3. Home PD. Impact of the UKPDS-an overview. Diabetic Med. 2008;25(suppl 2):2-8.
4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
5. Holman R, Paul S, Bethel M, Matthews D, Neil H. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
6. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care. 1998;21:1138-1145.
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
8. Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170:1892-1899.
9. Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: A cohort study. Ann Int Med. 2012;157:601-610.
10. Cheng YY, Leu HB, Chen TJ, et al. Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: A 4-year follow-up study. J Stroke Cerebrovasc Dis. 2014; 23:e99-e105.
11. Chang SH, Wu LS, Chiou MJ, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: A population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014; 13:123.
12. Roumie CL, Greevy RA, Grijalva CG, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014;311: 2288-2296.
13. U.K. Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes. 1995;44:1249-1258.
14. Solskov L, Løfgren B, Kristiansen SB, et al. Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration. Basic Clin Pharmacol Toxicol. 2008;103:82-87.
15. Paiva M, Riksen NP, Davidson SM, et al. Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol. 2009;53:373-378.
16. El Messaoudi S, Rongen GA, Riksen NP. Metformin therapy in diabetes: The role of cardioprotection. Curr Atherosclerosis Rep. 2013;15:314.
17. Jeppesen J, Zhou M, Chen Y, Reaven G. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care. 1994;17:1093-1099.
18. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care. 1993;16:621-629.
19. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med. 1991; 229:181-187.
20. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333:541-549.
21. Fanghänel G, Sánchez-Reyes L, Trujillo C, Sotres D, Espinosa-Campos J. Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care. 1996;19:1185-1189.
22. Giugliano D, De Rosa N, Di Maro G, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care. 1993;16:1387-1390.
23. Amador-Licona N, Guízar-Mendoza J, Vargas E, Sánchez-Camargo G, Zamora-Mata L. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus. Arch Med Res. 2000;31:571-575.
24. Goldberg R, Temprosa M, Otvos J, et al. Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2013;98:3989-3998.
25. Roumie CL, Huizinga MM, Liu X, et al. The effect of incident antidiabetic regimens on lipid profiles in veterans with type 2 diabetes: A retrospective cohort. Pharmacoepidemiol Drug Saf. 2011;20:36-44.
26. Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CDA, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: A systematic review. J Intern Med. 2004;256:1-14.
27. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37:1344-1350.
28. Sobel BE, Hardison RM, Genuth S, et al. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulinsensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2011;124:695-703.
29. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf. 1994;11: 223-241.
30. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997; 102:99-110.
31. Jackson RA, Hawa MI, Jaspan JB, et al. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes. 1987;36:632-640.
32. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia. 1999;42:406-412.
33. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care. 2000;23:1499-1504.
34. Ratner R, Goldberg R, Haffner S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005;28:888-894.
35. Klein W. Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy. Results of a prospective randomized study in 50 patients. Diabete Metab. 1991;17(1 Pt 2):235-240.
36. Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care. 1998;21:701-705.
37. UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care. 1998;21:87-92.
38. Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care. 1998;21:2135-2139.
39. Uehara MH, Kohlmann NE, Zanella MT, Ferreira SR. Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab. 2001;3:319-325.
40. Chu NV, Kong APS, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2002;25:542-549.
41. Calle-Pascual AL, Garcia-Honduvilla J, Martin-Alvarez PJ, et al. Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment. Diabete Metab. 1995;21:256-260.
42. Hermann LS, Scherstén B, Bitzén PO, Kjellström T, Lindgärde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care. 1994;17:1100-1109.
43. He H, Zhao Z, Chen J, et al. Metformin-based treatment for obesity-related hypertension: A randomized, doubleblind, placebo-controlled trial. J Hypertens. 2012;30:1430-1439.
44. Gauer O. Kreislauf des Blutes. In: Landois L, Rosemann HU, eds. Lehrbuch der Physiologie des Menschen. Berlin: Von Urban and Schwarzenberg; 1960: 95-135.
45. Roumie CL, Liu X, Choma NN, et al. Initiation of sulfonylureas versus metformin is associated with higher blood pressure at one year. Pharmacoepidemiol Drug Saf. 2012;21:515-523.
46. Abbink EJ, Pickkers P, Jansen van Rosendaal A, et al. Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients. Diabet Med. 2002; 19:136-143.
47. Manzella D, Grella R, Esposito K, Giugliano D, Barbagallo M, Paolisso G. Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: Effect of metformin administration. Am J Hypertens. 2004; 17:223-227.
48. van der Meer RW, Rijzewijk LJ, de Jong HW, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation. 2009;119:2069-2077.
49. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30:359-371.
50. Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: The NHANES III study. Mayo Clin Proc. 2005;80:1270-1277.
51. National Kidney F. KDOQI Clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012; 60:850-886.
52. Miles JM, Rule AD, Borlaug BA. Use of metformin in diseases of aging. Curr Diab Rep. 2014;14:490.
53. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf. 1999;20: 489-503.
54. Ekström N, Schiöler L, Svensson AM, et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: A cohort study from the Swedish National Diabetes Register. BMJ Open. 2012;2:e001076.
55. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: A systematic review. JAMA. 2014;312:2668-2675.
56. Protti A, Russo R, Tagliabue P, et al. Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication. Crit Care. 2010;14:R22.
57. Vasisht KP, Chen SC, Peng Y, Bakris GL. Limitations of metformin use in patients with kidney disease: Are they warranted Diabetes Obes Metab. 2010;12:1079-1083.
58. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010:CD002967.
59. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379.
60. Holstein A, Stumvoll M. Contraindications can damage your health-is metformin a case in point Diabetologia. 2005;48:2454-2459.
61. Hung AM, Roumie CL, Greevy RA, et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int. 2012;81:698-706.
62. Friesecke S, Abel P, Roser M, Felix SB, Runge S. Outcome of severe lactic acidosis associated with metformin accumulation. Crit Care. 2010;14:R226.
63. Frid A, Sterner GN, Löndahl M, et al. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: Clinical recommendations. Diabetes Care. 2010;33:1291-1293.
64. Christensen MMH, Brasch-Andersen C, Green H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011;21: 837-850.
65. Campbell IW, Menzies DG, Chalmers J, McBain AM, Brown IR. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete Metab. 1994; 20: 394-400.
66. Olsson SB, Halperin JL. Prevention of stroke in patients with atrial fibrillation. Sem Vasc Med. 2005;5:285-292.
67. Nielsen F, Christensen MMH, Brøsen K. Quantitation of metformin in human plasma and urine by hydrophilic interaction liquid chromatography and application to a pharmacokinetic study. Ther Drug Monit. 2014;36:211-217.
68. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: An update. Diabetes Care. 2004;27:1879-1884.
69. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108: 2941-2948.
70. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. New Engl J Med. 1998;338:265-266.
71. Masoudi FA, Wang Y, Inzucchi SE, et al. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA. 2003;290:81-85.
72. Inzucchi SE, Masoudi FA, McGuire DK. Metformin in heart failure. Diabetes Care. 2007;30:e129.
73. Nichols GA, Koro CE, Gullion CM, Ephross SA, Brown JB. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev. 2005;21:51-57.
74. Pantalone KM, Kattan MW, Yu C, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: A retrospective analysis. Acta Diabetol. 2009;46:145-154.
75. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345-2351.
76. Pocock SJ, McMurray JJV, Dobson J, et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:2641-2650.
77. Wohlfahrt P, Redfield M, Lopez-Jimenez F, et al. Impact of general and central adiposity on ventricular-arterial aging in women and men. JACC Heart Fail. 2014;2:489-499.
78. Alpert MA, Terry BE, Mulekar M, et al. Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. Am J Cardiol. 1997;80:736-740.
79. Mariotti R, Castrogiovanni F, Canale ML, Borelli G, Rondinini L. Weight loss and quality of life in chronic heart failure patients. J Cardiovasc Med (Hagerstown). 2008;9:576-580.
80. Peterson LR, Herrero P, Schechtman KB, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation. 2004;109:2191-2196.
81. Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1993;77:1287-1293.
82. Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol. 2000;278:H1345-H1351.
83. Viljanen APM, Karmi A, Borra R, et al. Effect of caloric restriction on myocardial fatty acid uptake, left ventricular mass, and cardiac work in obese adults. Am J Cardiol. 2009;103:1721-1726.
84. Packer M. Role of the sympathetic nervous system in chronic heart failure. A historical and philosophical perspective. Circulation. 1990;82(2 suppl 1):I1-I6.
85. Patel JN, Eisenhofer G, Coppack SW, Miles JM. Norepinephrine spillover in forearm and subcutaneous adipose tissue before and after eating. J Clin Endocrinol Metab. 1999;84:2815-2819.
86. Gudbjörnsdottir S, Friberg P, Elam M, Attvall S, Lonnroth P, Wallin BG. The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men. Blood Press. 1994;3:394-403.
87. Straznicky NE, Grima MT, Eikelis N, et al. The effects of weight loss versus weight loss maintenance on sympathetic nervous system activity and metabolic syndrome components. J Clin Endocrinol Metab. 2011;96:E503-E508.
88. Kern W, Peters A, Born J, Fehm HL, Schultes B. Changes in blood pressure and plasma catecholamine levels during prolonged hyperinsulinemia. Metabolism. 2005;54:391-396.
89. Perriello G, Misericordia P, Volpi E, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes. 1994;43:920-928.
90. Hou X, Song J, Li X-N, et al. Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. Biochem Biophys Res Comm. 2010;396:199-205.
91. Triggle CR, Ding H. A review of endothelial dysfunction in diabetes: A focus on the contribution of a dysfunctional eNOS. J Am Soc Hypertens. 4:102-115.
92. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494: 256-260.
93. Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabetic Med. 1998;15:651-656.
94. Wu MS, Johnston P, Sheu WH, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care. 1990;13:1-8.
95. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103:491-497.
96. Dandona P, Fonseca V, Mier A, Beckett AG. Diarrhea and metformin in a diabetic clinic. Diabetes Care. 1983;6:472-474.
97. Bailey CJ, Turner RC. Metformin. New Engl J Med. 1996;334:574-579.
98. Reinstatler L, Qi YP, Williamson RS, Garn JV, Oakley GP Jr. Association of biochemical B12 deficiency with metformin therapy and vitamin B12 supplements: The National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care. 2012;35:327-333.
99. Obeid R. Metformin causing vitamin B12 deficiency: A guilty verdict without sufficient evidence. Diabetes Care. 2014;37:e22-e23.